On November 26 and 27, a team from the Organisation of European Cancer Institutes (OECI) conducted an audit at the Clínic Barcelona Comprehensive Can1
Hospitals that are part of the C17 alliance have launched the C17 Integrated Cancer Network (XIC-C17), an initiative aimed at strengthening coordinat1
A study led by the Clínic Barcelona Comprehensive Cancer Center —a center driven by Clínic-IDIBAPS and the University of Barcelona (UB)— demonstrates1
Researchers from Clínic-IDIBAPS, within the Clínic Barcelona Comprehensive Cancer Center, and the spin-off Gyala Therapeutics have coordinated a stud1
The Clínic Barcelona Comprehensive Cancer Center (4CB), driven by Hospital Clínic Barcelona, IDIBAPS, and the University of Barcelona, has announced1
Hospital Clínic-IDIBAPS is the only hospital in Europe to have fully developed two academic CAR T-cell therapies that have been approved by a regulat1
The creation of the Clínic Barcelona Comprehensive Cancer Center represents a step forward in the integration of care, clinical research, translation1
Researchers at IDIBAPS- Hospital Clínic have developed and validated a new CAR-T therapy called ARI0003 at a preclinical level. The new therapy combi1
September 1st is World Chronic Lymphocytic Leukaemia (CLL) Day, the most common leukaemia in adults. Most patients with CLL respond well to treatment1
The Committee for the Evaluation of Medicinal Products for Human Use of the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved ARI01
